Conmed reports Q2 adjusted EPS 83c, consensus 79c

Reports Q2 revenue $317.652M, consensus $306.09M. “Our team drove excellent growth across both Orthopedics and General Surgery during the second quarter, building on the momentum we generated during the first three months of the year,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “We remain confident in our ability to grow above market and continue to deliver clinical innovation to our customers.”